Felden Hlaup 0,5 % Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

felden hlaup 0,5 %

pfizer aps - piroxicamum inn - hlaup - 0,5 %

Voltaren Hlaup 11,6 mg/g Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

voltaren hlaup 11,6 mg/g

haleon denmark aps - diclofenacum tvíetýlamín - hlaup - 11,6 mg/g

Trileptal Mixtúra, dreifa 60 mg/ml Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

trileptal mixtúra, dreifa 60 mg/ml

novartis healthcare a/s - oxcarbazepinum inn - mixtúra, dreifa - 60 mg/ml

Sandimmun Neoral Mixtúra, lausn 100 mg/ml Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

sandimmun neoral mixtúra, lausn 100 mg/ml

novartis healthcare a/s - ciclosporinum inn - mixtúra, lausn - 100 mg/ml

Differin Hlaup 1 mg/g Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

differin hlaup 1 mg/g

galderma nordic ab - adapalenum inn - hlaup - 1 mg/g

Dermovat Krem 0,5 mg/g Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

dermovat krem 0,5 mg/g

glaxosmithkline pharma a/s - clobetasolum própíónat - krem - 0,5 mg/g

Dermovat Smyrsli 0,5 mg/g Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

dermovat smyrsli 0,5 mg/g

glaxosmithkline pharma a/s - clobetasolum própíónat - smyrsli - 0,5 mg/g

Diklofenak Apofri Hlaup 11,6 mg/g Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

diklofenak apofri hlaup 11,6 mg/g

evolan pharma ab - diclofenacum tvíetýlamín - hlaup - 11,6 mg/g

Xylocain Smyrsli 50 mg/g Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

xylocain smyrsli 50 mg/g

aspen pharma trading limited - lidocainum inn - smyrsli - 50 mg/g

Phelinun Unione Europea - islandese - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - Æxlishemjandi lyf - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.